Recruiting Macular Degeneration Studies in La Jolla
Extension Study for the Port Delivery System With Ranibizumab (Portal)
This study will evaluate the long-term safety and tolerability of the Port Delivery System with ranibizumab (PDS) (100 mg/mL) in participants with neovascular age-related macular degeneration (nAMD) w...
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
This study is researching experimental (study) drugs called pozelimab and cemdisiran. The study is focused on participants who have Geographic Atrophy (GA) caused by Age-related Macular Degeneration (...
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). Wet AMD is characterized by ...
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
The purpose of this study is to assess the long-term safety and tolerability after an intravitreal injection (a shot of medicine into the eye) of JNJ-81201887 administered in parent clinical studies....
About Macular Degeneration Clinical Trials in La Jolla
Age-related macular degeneration (AMD) is the leading cause of severe vision loss in Americans over 50, affecting over 11 million people. Wet (neovascular) AMD involves abnormal blood vessel growth under the retina, while dry AMD involves gradual thinning of the macula and accumulation of drusen deposits. Current treatment for wet AMD relies on anti-VEGF injections (ranibizumab, aflibercept, faricimab), with newer high-dose and extended-interval formulations reducing treatment burden. For geographic atrophy (advanced dry AMD), complement inhibitors like pegcetacoplan (Syfovre) represent the first approved treatments. Clinical trials are testing gene therapies, implantable drug delivery systems, stem cell therapies, and novel targets beyond VEGF for both wet and dry AMD.
There are currently 4 macular degeneration clinical trials recruiting participants in La Jolla, CA. These studies are seeking a combined 2,946 participants. Research is being sponsored by Hoffmann-La Roche, Regeneron Pharmaceuticals, AbbVie and 1 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Macular Degeneration Clinical Trials in La Jolla — FAQ
Are there macular degeneration clinical trials in La Jolla?
Yes, there are 4 macular degeneration clinical trials currently recruiting in La Jolla, CA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in La Jolla?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the La Jolla research site will contact you about next steps.
Are clinical trials in La Jolla free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many La Jolla studies also compensate for your time and travel.
What macular degeneration treatments are being tested?
The 4 active trials in La Jolla are testing new therapies including novel drugs, biologics, and treatment approaches for macular degeneration.
Data updated March 2, 2026 from ClinicalTrials.gov